Discovery of novel cannabinoid receptor ligands by a virtual screening approach: Further development of 2,4,6-trisubstituted 1,3,5-triazines as CB2 agonists

European Journal of Pharmaceutical Sciences

Volumn 48, Issue 1-2, 2013, Pages 9-20

  Yrjölä, Sari ^a   Kalliokoski, Tuomo ^a,b   Laitinen, Tuomo ^a   Poso, Antti ^a   Parkkari, Teija ^a   Nevalainen, Tapio ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cannabinoid receptor; CB1; CB2 agonists; Synthesis; Triazines; Virtual screening

Indexed keywords

2 CHLORO 4 ETHOXY 6 (4 METHYLPIPERIDIN 1 YL) 1,3,5 TRIAZINE; 2 CHLORO 4 ETHOXY 6 PROPYL 1,3,5 TRIAZINE; 2 ETHOXY 4 (4 METHYLPIPERIDIN 1 YL) 6 PROPYL 1,3,5 TRIAZINE; 4 CHLORO 6 ETHOXY N PHENETHYL 1,3,5 TRIAZIN 2 AMINE; 4 CHLORO 6 ETHOXY N PHENYL 1,3,5 TRIAZIN 2 AMINE; 4 CHLORO N CYCLOPENTYL 6 (4 METHYLPIPERIDIN 1 YL) 1,3,5 TRIAZIN 2 AMINE; 4 CHLORO N CYCLOPENTYL 6 ETHOXY 1,3,5 TRIAZIN 2 AMINE; 4 ETHOXY 6 (4 METHYLPIPERIDIN 1 YL) N PHENYL 1,3,5 TRIAZIN 2 AMINE; 4 ETHOXY 6 (4 METHYLPIPERIDIN 1 YL) N PROPYL 1,3,5 TRIAZIN 2 AMINE; AMINE; CANNABINOID 2 RECEPTOR AGONIST; N (4 BUTYLPHENYL) 4 ETHOXY 6 (4 METHYLPIPERIDIN 1 YL) 6 PROPYL 1,3,5 TRIAZIN 2 AMINE; N (ADAMANTAN 1 YL) 2 CHLORO 4 ETHOXY 6 (4 METHYLPIPERIDIN 1 YL) 1,3,5 TRIAZIN 2 AMINE; N BENZYL 4 CHLORO 6 ETHOXY 1,3,5 TRIAZIN 2 AMINE; N BENZYL 4 ETHOXY 6 (4 METHYLPIPERIDIN 1 YL) 1,3,5 TRIAZIN 2 AMINE; N CYCLOPENTYL 4 (4 METHYLPIPERIDIN 1 YL) 6 PROPOXY 1,3,5 TRIAZIN 2 AMINE; N CYCLOPENTYL 4 (4 METHYLPIPERIDIN 1 YL) 6 PROPYL 1,3,5 TRIAZIN 2 AMINE; N CYCLOPENTYL 4 [(1,1,1,3,3,3 HEXAFLUOROPROPAN 2 YL)OXY)] 6 (4 METHYLPIPERIDIN 1 YL) 1,3,5 TRIAZIN 2 AMINE; N CYCLOPENTYL 4 ETHOXY 6 (4 METHYLPIPERIDIN 1 YL) 1,3,5 TRIAZIN 2 AMINE; N CYCLOPENTYL 4 ETHOXY 6 (PIPERIDIN 1 YL) 1,3,5 TRIAZIN 2 AMINE; N CYCLOPENTYL 4 ISOPROPOXY 6 (4 METHYLPIPERIDIN 1 YL) 6 PROPYL 1,3,5 TRIAZIN 2 AMINE; N,N DIALLYL 4 ETHOXY 6 (4 METHYLPIPERIDIN 1 YL) 1,3,5 TRIAZIN 2 AMINE; N2 (4 BUTYLPHENYL) N4 CYCLOPENTYL 6 ETHOXY 1,3,5 TRIAZINE 2,4 DIAMINE; N2 BENZYL N4 CYCLOPENTYL 6 ETHOXY 1,3,5 TRIAZINE 2,4 DIAMINE; N2 CYCLOPENTYL 6 (4 METHYLPIPERIDIN 1 YL) N4 6 PHENYL 1,3,5 TRIAZINE 2,4 DIAMINE; N2 CYCLOPENTYL 6 (4 METHYLPIPERIDIN 1 YL) N4 6 PROPOXY 1,3,5 TRIAZINE 2,4 DIAMINE; N2 CYCLOPENTYL 6 ETHOXY N4 PHENYL 1,3,5 TRIAZIN 2 AMINE; N2 CYCLOPENTYL 6 ETHOXY N4 PHENYL 1,3,5 TRIAZINE 2,4 DIAMINE; N2 CYCLOPENTYL 6 ETHOXY N4 PROPYL 1,3,5 TRIAZINE 2,4 DIAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ALGORITHMS; LIGANDS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES;

EID: 84869868200     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.10.020     Document Type: Article

References (28)

1. K.V. Balakin, S.E. Tkachenko, S.A. Lang, I. Okun, A.A. Ivashchenko, and N.P. Savchuk Property-based design of GPCR-targeted library J. Chem. Inf. Comput. Sci. 42 2002 1332 1342
2. B.S. Basavarajappa Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity Curr. Neuropharmacol. 5 2007 81 97
3. Chemical Computing Group Inc.; 2008. 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada. Molecular Operating Environment (MOE), version 2008.10. < http://www.chemcomp.com >.
4. Coburn, G.A.; Han, A.Q.; Provoncha, K.P.; Rotshteyn, Y.; 2009. Progenics Pharmaceuticals, Inc.; WO/2009/091388 A2.
5. V. Di Marzo Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug. Discov. 7 2008 438 455
6. J. Gasteiger, and M. Marsili A new model for calculating atomic charges in molecules Tetrahedron Lett. 34 1978 3181 3184
7. T.J. Hou, K. Xia, W. Zhang, and X.J. Xu ADME evaluation in drug discovery. 4. Prediction of aqueous solubility based on atom contribution approach J. Chem. Inf. Comput. Sci. 44 2004 266 275
8. J.J. Irwin, and B.K. Shoichet ZINC-a free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 45 2005 177 182
9. E. Kirilly, X. Gonda, and G. Bagdy CB1 receptor antagonists: new discoveries leading to new perspectives Acta Physiol. 205 2012 41 60
10. D.R. Lide CRC Handbook of Chemistry and Physics 1994 CRC Press
11. B. Lutz Molecular biology of cannabinoid receptors Prostagland. Leukot Essent Fatty Acids 66 2002 123 142
12. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, and T.I. Bonner Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 1990 561 564
13. F. Milletti, L. Storchi, G. Sforna, and G. Cruciani New and original pKa prediction method using grid molecular interaction fields J. Chem. Inf. Model. 47 2007 2172 2181
14. Molecular Networks GmbH, xxxx. Erlangen, Germany. CORINA, version 3.2; ROTATE, version 1.4.
15. A. Moriconi, I. Cerbara, M. Maccarrone, and A. Topai GPR55: current knowledge and future perspectives of a purported "Type-3" cannabinoid receptor Curr. Med. Chem. 17 2010 1411 1429
16. S. Munro, K.L. Thomas, and M. Abu-Shaar Molecular characterization of a peripheral receptor for cannabinoids Nature 365 2003 61 65
17. N.M. O'Boyle, M. Banck, C.A. James, C. Morley, T. Vandermeersch, and G.R. Hutchison Open babel: an open chemical toolbox J. Cheminf. 3 2011 33
18. T.I. Oprea Property distribution of drug-related chemical databases J. Comput. Aided Mol. Des. 14 2000 251 264
19. P. Pacher, S. Bátkai, and G. Kunos The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol. Rev. 58 2006 389 462
20. P. Pacher, and R. Mechoulam Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog. Lipid Res. 50 2011 193 211
21. T. Rönkkö, A.J. Tervo, J. Parkkinen, and A. Poso BRUTUS: optimization of a grid-based similarity function for rigid-body molecular superposition. II. Description and characterization J. Comput. Aided Mol. Des. 20 2006 227 236
22. 1 and cannabinoid CB1 receptors Br. J. Pharmacol. 140 2003 1451 1459
23. J.R. Savinainen, T. Kokkola, O.M.H. Salo, A. Poso, T. Järvinen, and J.T. Laitinen Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor Br. J. Pharmacol. 45 2005 636 645
24. Schrödinger LLC, New York, USA, 2008. LigPrep, EpiK, ConfGen.
25. J.T. Thurston, J.R. Dudley, D.W. Kaiser, I. Hechenbleikner, F.C. Schaefer, and D. Holm-Hansen Cyanuric chloride derivates. I. Aminochloro-s-triazines J. Am. Chem. Soc. 73 1951 2981 2983
26. A.J. Tervo, T. Rönkkö, T.H. Nyrönen, and A. Poso BRUTUS: optimization of a grid-based similarity function for rigid-body molecular superposition. 1. Alignment and virtual screening applications J Med Chem. 48 2005 4076 4086
27. S.A. Wildman, and G.M. Crippen Prediction of physicochemical parameters by atomic contributions J. Chem. Inf. Comput. Sci. 39 1999 868 873
28. M.L. Yates, and E.L. Barker Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol Mol. Pharmacol. 76 2009 11 17